2017. Péntek M et al. – New insights into the burden and costs of multiple sclerosis in Europe: Results for Hungary

 

Péntek M, Kobelt G, Berg J, Capsa D, Dalén J, Bíró Z, Mátyás K, Komoly S; European Multiple Sclerosis Platform. New insights into the burden and costs of multiple sclerosis in Europe: Results for Hungary. Mult Scler. 2017 Aug;23(2_suppl):91-103.

https://www.ncbi.nlm.nih.gov/pubmed/28643591

Read Full Article – Open Access

Abstract

INTRODUCTION: To estimate the value of interventions in multiple sclerosis (MS) – where lifetime costs and outcomes cannot be observed – outcome data have to be combined with costs. This requires that cost data be regularly updated.

OBJECTIVES AND METHODS: This study is part of a cross-sectional retrospective study in 16 countries collecting data on resource consumption, work capacity, health-related quality of life (HRQoL) and prevalent symptoms for patients with MS. Descriptive analyses are presented by level of disability, from the societal perspective, in HUF 2015.

RESULTS: A total of 521 patients (mean age 47 years) participated; 85% were below retirement age, and of these, 47% were employed. Employment was related to disability and MS affected productivity at work for 82% of those working. Overall, 94% and 66% of patients experienced fatigue and cognitive difficulties as a problem, respectively. The mean utility and annual costs were 0.691 and 3,432,000HUF at Expanded Disability Status Scale (EDSS) 0-3, 0.491 and 5,262,000HUF at EDSS 4-6.5 and 0.076 and 6,235,000HUF at EDSS 7-9, respectively. The average cost of a relapse was estimated at 240,500HUF.

CONCLUSION: This study illustrates the burden of MS on Hungarian patients and provides current data that are important for the development of health policies.